Arthritis Research & Therapy

Arthritis Research & Therapy (Arthritis Res. Ther.) is an open access rheumatology journal published by BioMed Central. Launched in 1999 as Arthritis Research and carrying its present name since 2003, it was among the first fully open access titles in rheumatology. It publishes continuously and had a 2025 impact factor of 5.4.《关节炎研究与治疗》（Arthritis Research & Therapy''''，缩写 Arthritis Res. Ther.''）是（BioMed Central）出版的开放获取风湿病学期刊，1999 年创刊时名为《关节炎研究》，2003 年起改用现名，是风湿免疫领域最早采取完全开放获取的刊物之一。该刊为连续出版，二〇二五年影响因子为 5.4。

Scope

The journal defines itself as a rheumatology title organised around translation: whether a study is done in the laboratory or the clinic, it has to advance the understanding of mechanism or of diagnosis and treatment, and purely descriptive work is not given priority. Coverage runs from mechanism to trial, and concentrates on:本刊的定位是「以转化为轴心的风湿病学刊物」：一项研究无论在实验室还是在临床完成，都要指向对疾病机制或诊疗的实际推进，纯描述性工作不在本刊优先考虑之列。收文覆盖从机制到试验的完整链条，重点包括：

• Musculoskeletal and rheumatic disease: rheumatoid arthritis, spondyloarthritis, osteoarthritis and crystal arthropathies, and systemic lupus erythematosus and connective tissue disease.肌肉骨骼与风湿病： 类风湿关节炎、脊柱关节炎、骨关节炎与晶体性关节病、系统性红斑狼疮与结缔组织病。

• Inflammation and immune mechanism: innate and adaptive immunity, cytokines and signalling pathways, the initiation and resolution of inflammation, and the breakdown of self-tolerance.炎症与免疫机制： 先天与适应性免疫、细胞因子与信号通路、炎症的启动与消退、自身耐受的破坏机制。

• Damage and repair: cartilage and bone metabolism, the cellular basis of erosion and repair, tissue remodelling and fibrosis, and the biology of pain.损伤与修复： 软骨与骨代谢、骨侵蚀与修复的细胞基础、组织重塑与纤维化、疼痛机制的生物学研究。

• Clinical trials and treatment: early and late phase therapeutic trials, biological and targeted agents, head-to-head comparisons of treatment strategies, and real-world effectiveness and safety.临床试验与治疗： 早期与晚期治疗性试验、生物制剂与靶向药物、治疗策略的头对头比较、真实世界疗效与安全性。

• Epidemiology and genetics: disease burden and risk factors, genetic susceptibility and epigenetics, biomarkers and disease classification, and outcome studies at population level.流行病学与遗传： 疾病负担与危险因素、遗传易感性与表观遗传、生物标志物与疾病分型、人群层面的结局研究。

• Imaging and outcomes: imaging and the assessment of disease activity, patient-reported outcomes and functional scales, and quantitative assessment of radiographic progression and structural damage.影像与结局： 影像学与疾病活动度评估、患者报告结局与功能量表、影像学进展与结构损伤的定量评价。

The journal has been fully open access since its launch, with papers deposited in PubMed Central. The publisher reports a median of eleven days from submission to first editorial decision, and publishes neither an acceptance rate nor a full set of review timings.本刊自创刊起即实行完全开放获取，论文同时存入（PubMed Central）；出版方公布投稿至首次编辑决定的中位数为十一天，未公布录用比例与完整的审稿时效。^[1]

History

• Founding (1999): the journal was launched in 1999 as Arthritis Research with print ISSN 1465-9905. Its founding editors were Peter E. Lipsky and Sir Ravinder N. Maini, and the first paper appeared in June 1999.创刊（1999年）： 1999 年创刊，创刊刊名为《关节炎研究》，印刷 ISSN 为 1465-9905，创刊主编为（Peter E. Lipsky）与（Ravinder N. Maini）爵士，创刊首篇论文发表于 1999 年 6 月。^[2]

• Two accounts of the rename: the publisher's own page gives only the 1999 launch and no year of renaming, while the NLM catalogue records the present-name entity as beginning with volume 5, issue 1 in 2003. The two accounts stand together, and the volume numbering has been continuous throughout, a change of name rather than of journal.改名时点的两说： 出版方官方页只给出 1999 年创刊、未列改名年份，而 NLM 目录将现名实体的起始年记为 2003 年第 5 卷第 1 期；两说并存，本刊卷号自创刊起连续，改卷不换刊。^[3]

• Move online (2010): full text has been available online since the launch, and the print edition ceased with volume 12, issue 6 in 2010. Since then the journal has published continuously online with no issue numbers, and the bimonthly records surviving in library catalogues are stale.转为纯在线（2010年）： 本刊自创刊起即提供在线全文，印刷版出至 2010 年第 12 卷第 6 期后停刊，此后为纯在线连续出版，不再设期号，各图书馆目录中留存的双月刊著录属陈旧数据。^[3]

• Metrics and indexing: the 2025 impact factor is 5.4 with a five-year figure of 5.1, and the publisher publishes no CiteScore. The journal is indexed in the Science Citation Index Expanded, Scopus and MEDLINE, and in 2026 established a trusted reviewer board to strengthen continuity in peer review.指标与收录： 2025 年影响因子 5.4、五年影响因子 5.1，出版方未公布引用分数；本刊被科学引文索引扩展版、Scopus 与 MEDLINE 收录，2026 年新设可信评审人委员会以加强审稿连续性。^[4]

Editors

The journal is run by two co-editors-in-chief, one in the United Kingdom and one in the United States, covering clinical rheumatology and basic immunology respectively. The founding arrangement was likewise a dual editorship split between a clinician and an immunologist, and that structure has persisted ever since.本刊现由两名主编共同主持，两人分处英国与美国，分别覆盖临床风湿病学与基础免疫学方向；创刊时同样采取双主编制，分别由临床学者与免疫学家担任，这一结构自创刊起延续至今。^[2]

• Present co-editors-in-chief: Christopher Buckley of the University of Oxford and Harris Perlman of Northwestern University run the journal jointly现任共同主编： （Christopher Buckley）供职于牛津大学，（Harris Perlman）供职于西北大学，两人共同主持本刊；出版方未公布各自的就任年份。 the publisher does not state the year of either appointment.^[2]

• Founding editors: Peter E. Lipsky and Sir Ravinder N. Maini founded the journal together, respectively leading figures of North American and British rheumatology and immunology创刊主编： （Peter E. Lipsky）与（Ravinder N. Maini）爵士共同创办本刊，两人分别为北美与英国风湿免疫学的代表人物；后者的抗肿瘤坏死因子治疗研究，正是本刊「转化为轴心」定位的来源之一。 the latter's work on anti-tumour necrosis factor therapy is one of the sources of the journal's translational orientation.^[2]

• Open access standing: the journal has been fully open access since its launch and was among the first rheumatology titles to show that the model works for high-quality clinical research. Its papers are deposited automatically in PubMed Central, forming a freely accessible literature base for the field.开放获取地位： 本刊自创刊起即为完全开放获取，是最早证明开放获取模式可用于高水平临床研究的风湿病刊物之一，其论文自动存入（PubMed Central），构成该领域可自由获取的文献基础。^[1]